Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: US approval for Lilly’s obesity drug; a look at the future of the obesity market; BMS’s ADC deal; Roche’s MS plans; and one Chinese firm’s CAR-T plans.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 10 November 2023, including: US approval for Eli Lilly and Company’s obesity drug; a look at the future of the obesity market; Bristol Myers Squibb Company’s ADC deal; Roche Holding AG’s MS plans; and one Chinese firm’s CAR-T plans.

This and all our other podcasts are available on the Citeline channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode: 

(Also see "Lilly Plans ‘Big, Bold’ Launch For Zepbound" - Scrip, 8 Nov, 2023.)

(Also see "The Next Frontier In Obesity: Better, Not More, Weight Loss" - Scrip, 6 Nov, 2023.)

(Also see "BMS Spends $100m On Orum’s Antibody-Guided Protein Degrader" - Scrip, 7 Nov, 2023.)

(Also see "How Roche Plans To Stay Ahead In MS And Catch Up In Alzheimer’s" - Scrip, 3 Nov, 2023.)

(Also see "Podcast: China CEO Interview – Gracell Aims To Enter US CAR-T Sector Through Partnerships, Faster Delivery" - Scrip, 6 Nov, 2023.)

 

 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel